Radionuclide therapy of hepatocellular carcinoma

Biomedical Imaging and Intervention Journal

Volumn 2, Issue 3, 2006, Pages

  Sundram, Felix X ^a  

^a SUBANG JAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Hepatocellular carcinoma; Iodine 131; Lipiodol; Rhenium 188; Yttrium 90 microspheres

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CHITOSAN; CORTICOSTEROID; EPIRUBICIN; FERRITIN ANTIBODY; FLUOROURACIL; GLASS; HOLMIUM; IODINATED POPPYSEED OIL; IODINE 131; MACROSALB TC 99M; MICROSPHERE; NONSTEROID ANTIINFLAMMATORY AGENT; RESIN; RHENIUM 188; TAMOXIFEN; YTTRIUM 90;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREMS RADIATION; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEMATOLOGIC DISEASE; HUMAN; ILEUS; LIVER ANGIOGRAPHY; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG DISEASE; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PORTAL VEIN THROMBOSIS; RADIATION DOSE; RADIATION PNEUMONIA; RADIOACTIVITY; RADIOISOTOPE THERAPY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 57149108708     PISSN: None     EISSN: 18235530     Source Type: Journal    
DOI: 10.2349/biij.2.3.e40     Document Type: Review

References (36)

1. Bosch FX, Munoz N. Hepatocellular carcinoma in the world: epidemiologic questions. Tabor E, DiBisceglie AM, Purcell RH, eds. Etiology, Pathology, and Treatment of Hepatocellular Carcinoma in North America. Advances in Applied Biotechnology Series. Vol. 13. Houston, USA: Portfolio Publishing, 1991:5-54.
2. Okuda K, Fujimoto I, Hanai A, et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47(18):4967-72.
3. Primary liver cancer in Japan. Sixth report. The Liver Cancer Study Group of Japan. Cancer 1987;60(6):1400-11.
4. Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992;69(4):925-9.
5. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210(3):655-61.
6. Iannitti DA, Dupuy DE, Mayo-Smith WW, et al. Hepatic radiofrequency ablation. Arch Surg 2002;137(4):422-6; discussion 427.
7. Zhou XD, Yu YQ, Tang ZY. An 18-year study of cryosurgery in the treatment of primary liver cancer. Asian J Surg 1992;15:43-7.
8. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352(9121):17-20.
9. Feun LG, Savaraj N, Hung S, et al. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 1994;17(5):393-5.
10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37(2):429-42.
11. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224(1):47-54.
12. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26(5):1156-61.
13. Tian JH, Xu BX, Zhang JM, et al. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med 1996;37(6):958-63.
14. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35(8):1313-8.
15. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35(11):1782-7.
16. Bhattacharya S, Novell JR, Dusheiko GM, et al. Epirubicin-Lipiodol chemotherapy versus 13 liodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76(11):2202-10.
17. Risse JH, Grunwald F, Kersjes W, et al. Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 2000;15(1):65-70.
18. Gyves JW, Ziessman HA, Ensminger WD, et al. Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT). J Nucl Med 1984;25(9):972-7.
19. Shepherd FA, Rotstein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992;70(9):2250-4.
20. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35(10):1637-44.
21. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40(3):583-92.
22. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41(10):1673-81.
23. Yan ZP, Lin G, Zhao HY, et al. An experimental study and clinical pilot trials on yttrium-90 glass microsphercs through the hepatic artery for treatment of primary liver cancer. Cancer 1993;72(11):3210-5.
24. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II stndy. Br J Cancer 1994;70(5):994-9.
25. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S194-205.
26. Jeong JM, Kim YJ, Lee YS, et al. Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28(2):197-204.
27. Lee YS, Jeong JM, Kim YJ, et al. Synthesis of 188 Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23(3):237-42.
28. Sundram FX, Jeong JM, Zanzonico P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 2002;1:5-11.
29. Sundram F, Chau TC, Onkhuudai P, et al. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2004;31(2):250-7.
30. Lambert B, Bacher K, Defreyne L, et al. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006;33(3):344-52.
31. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353(9155):797-801.
32. Partensky C, Sassolas G, Henry L, et al. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000;135(11):1298-300.
33. Keng GH, Sundram FX, Yu SW, et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates. Ann Acad Med Singapore 2002;31(3):382-6.
34. Liu L, Jiang Z, Teng GJ, et al. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma. World J Gastroenterol 1999;5(6):492-505.
35. Kotzerke J, Liepe K, Brogsitter G, et al. First results of Re-188 microspheres in selective hepatic radioembolisation. J Nucl Med 2005;46:449P.
36. Ryu JM, Chung SH, Oh YH, et al. Development of Radiopharmaceutical DW 166 HC (Holmium-166 chitosan complex chelate compound) for anticancer agent. Cancer Detect Prev 2000;24 (supp 1).